Irinotecan liposomal - CSPC Ouyi Pharmaceutical
Alternative Names: Irinotecan liposome injection - CSPC Ouyi PharmaceuticalLatest Information Update: 16 Jul 2024
At a glance
- Originator CSPC Ouyi Pharmaceutical
- Developer CSPC Ouyi Pharmaceutical; CSPC Pharmaceutical Group
- Class Alkaloids; Antineoplastics; Camptothecins; Carboxylic acids; Esters; Indolizines; Piperidines; Pyrans; Quinolines; Small molecules
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Adenocarcinoma; Biliary cancer
- Phase I Breast cancer
- Clinical Phase Unknown Pancreatic cancer
Most Recent Events
- 16 Jul 2024 Phase-II clinical trials in Biliary cancer (combination therapy) (unspecified route) prior to July 2024
- 18 Jun 2024 CSPC Ouyi Pharmaceutical plans a clinical trial for Biliary Cancer (Combination-therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater, In adults, In the elderly) (IV, Infusion), in July 2024 (NCT06463548)
- 31 May 2024 Efficacy and adverse event data from a phase I trial in Breast cencer presented at the 60th Annual Meeting of the American Society of Clinical Oncology